GH Research plc released a corporate presentation highlighting its lead program GH001, an inhaled mebufotenin (5-MeO-DMT) candidate for treatment-resistant depression. The company outlined its pipeline and development plans, including a global Phase 3 program for GH001 targeted to start in 2026, following completion of a randomized, double-blind, placebo-controlled Phase 2b trial and an open-label extension. The presentation also noted ongoing Phase 1 pharmacokinetic work with a proprietary device and described GH002, an intravenous mebufotenin program with a completed Phase 1 healthy volunteer trial and an IND submission milestone. The presentation reported Phase 2b results in TRD showing a placebo-adjusted least-squares mean difference in MADRS change from baseline of -15.5 at Day 8 (P<0.0001; Cohen’s d = -2.0), and remission rates of 57.5% at Day 8 for GH001 versus 0% for placebo. In the open-label extension, the company reported a 73% remission rate at approximately six months among completers, with patients receiving a mean of four treatments, and stated a median psychoactive experience duration of 11 minutes across double-blind and open-label treatments. Cash, cash equivalents and marketable securities were reported at $280.7 million as of December 31, 2025. You can access the full presentation through the link below. https://clinicaltrials.gov/study/NCT05800860

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GH Research plc published the original content used to generate this news brief on March 05, 2026, and is solely responsible for the information contained therein.